Stumpf M, Hasenburg A, Riener M-O, Jütting U, Wang C, Shen Y, Orlowska-Volk M, Fisch P, Wang Z, Gitsch G, Werner M, Lassmann S
Department of Obstetrics and Gynecology, Albert-Ludwigs-University, Freiburg 79106, Germany.
Br J Cancer. 2009 Nov 3;101(9):1513-21. doi: 10.1038/sj.bjc.6605274. Epub 2009 Sep 29.
The aim of this study was to investigate the prognostic effect of tumour-infiltrating lymphocytes (TILs) in serous stage III ovarian carcinoma to determine TIL clonality and to correlate this to Her2/neu expression.
Formalin-fixed and paraffin-embedded ovarian carcinomas were examined for CD20-, CD3-, CD4- and CD8-positive lymphocytes (n=100), and for Her2/neu-positive tumour cells (n=55/100) by immunohistochemistry. Clonality analysis was carried out by T-cell receptor gamma (TCRgamma) gene rearrangements (n=93/100). Statistical analyses included experimental and clinico-pathological variables, as well as disease-free (DFS) and overall (OS) survival.
CD20-positive B lymphocytes were present in 57.7% (stromal)/33.0% (intraepithelial) and CD3-positive T lymphocytes in 99.0% (stromal)/90.2% (intraepithelial) of ovarian carcinomas. Intraepithelial CD3-positive T lymphocytes were correlated with improved DFS in optimally debulked patients (P=0.0402). Intraepithelial CD8-positive T lymphocytes were correlated with improved OS in all optimally debulked patients (P=0.0201) and in those undergoing paclitaxel/carboplatin therapy (P=0.0092). Finally, rarified and clonal TCRgamma gene rearrangements were detected in 37 out of 93 (39.8%) and 15 out of 93 (16.1%) cases, respectively. This was marginally associated with improved DFS (P=0.0873). Despite a significant correlation of HER2/neu status and intraepithelial CD8-positive lymphocytes (P=0.0264), this was non-directional (R=-0.257; P=0.0626).
Improved survival of ovarian cancer patients is related to the infiltration, clonal selection and intraepithelial persistence of T lymphocytes.
本研究旨在探讨肿瘤浸润淋巴细胞(TILs)在浆液性III期卵巢癌中的预后作用,确定TIL的克隆性,并将其与Her2/neu表达相关联。
通过免疫组织化学检查福尔马林固定石蜡包埋的卵巢癌组织中CD20、CD3、CD4和CD8阳性淋巴细胞(n = 100)以及Her2/neu阳性肿瘤细胞(n = 55/100)。通过T细胞受体γ(TCRγ)基因重排进行克隆性分析(n = 93/100)。统计分析包括实验和临床病理变量,以及无病生存期(DFS)和总生存期(OS)。
57.7%(间质)/33.0%(上皮内)的卵巢癌组织中存在CD20阳性B淋巴细胞,99.0%(间质)/90.2%(上皮内)存在CD3阳性T淋巴细胞。在肿瘤细胞减灭术满意的患者中,上皮内CD3阳性T淋巴细胞与DFS改善相关(P = 0.0402)。在所有肿瘤细胞减灭术满意的患者中,上皮内CD8阳性T淋巴细胞与OS改善相关(P = 0.0201),在接受紫杉醇/卡铂治疗的患者中也相关(P = 0.0092)。最后,在93例病例中的37例(39.8%)和93例中的15例(16.1%)分别检测到稀少和克隆性TCRγ基因重排。这与DFS改善略有相关(P = 0.0873)。尽管HER2/neu状态与上皮内CD8阳性淋巴细胞有显著相关性(P = 0.0264),但这种相关性无方向性(R = -0.257;P = 0.0626)。
卵巢癌患者生存期的改善与T淋巴细胞的浸润、克隆选择和上皮内持续存在有关。